UIMF:F:F-UBS ETF SICAV - MSCI Europe UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 17.026

Change

+0.12 (+0.71)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-7.46 (-1.28%)

USD 111.88B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.20 (-0.39%)

USD 106.38B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.87 (-1.51%)

USD 105.77B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.05 (-0.35%)

USD 62.83B
VUSA:F Vanguard Funds Public Limited ..

-1.32 (-1.27%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-6.25 (-2.60%)

USD 51.55B
XJSE:F Xtrackers II - Japan Governmen..

-0.22 (-2.84%)

USD 43.00B
0ZC:F Zscaler Inc

+7.08 (+4.05%)

USD 37.92B
BSND:F Danone SA

+0.40 (+2.94%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing UIMF:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.59% 86% B+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.59% 85% B 77% C+
Trailing 12 Months  
Capital Gain 14.19% 68% D+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.19% 65% D 56% F
Trailing 5 Years  
Capital Gain 61.29% 67% D+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.29% 67% D+ 51% F
Average Annual (5 Year Horizon)  
Capital Gain 11.82% 73% C 67% D+
Dividend Return 11.82% 71% C- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.07% 57% F 86% B+
Risk Adjusted Return 97.97% 88% B+ 92% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike